BioCentury | May 29, 2019
Company News

CHMP against Emmaus' sickle cell therapy, Taiwan Liposome's doxorubicin

...and free radical scavenger is approved in the U.S. The committee backed approval of Cufence trientine hydrochloride...
...a chelating compound for removal of excess copper from the body, in the U.S. as Syprine...
...Informal) Radicut, edaravone (MCI-186, radicava) Syprine, trientine hydrochloride Emmaus Life Sciences Inc. Mitsubishi Tanabe Pharma Corp. Novartis AG Taiwan Liposome Co. Ltd. Cufence trientine hydrochloride Doxolipad...
BioCentury | Apr 20, 2018
Finance

Refilling Alexion’s cupboard

...to 48 weeks. SOC consists of oral metal chelating compounds such as Cuprimine penicillamine and Syprine...
...Drug designation in the U.S. and EU. Valeant booked 2017 sales of $91 million for Syprine...
...therapy (ALXN1101) Decuprate, bis-choline tetrathiomolybdate (WTX101, atn-224) Kanuma, sebelipase alfa (sbc-102, rhLAL) RhNAGLU (SBC-103) Strensiq, asfotase alfa (ENB-0040) Subcutaneous ALXN1210 Syprine, trientine hydrochloride Alexion...
BioCentury | Jul 21, 2016
Distillery Therapeutics

Therapeutics: ATPase Cu++ transporting β polypeptide (ATP7B)

...and liver failure, and increased survival compared with the standards of care D-penicillamine and Syprine trientine hydrochloride...
...trientine hydrochloride. Next steps could include formulating methanobactin for oral delivery. Valeant Pharmaceuticals International Inc. markets Syprine...
BioCentury | May 8, 2014
Distillery Therapeutics

Indication: Cancer

...Zelboraf vemurafenib to treat melanoma. Valeant Pharmaceuticals International Inc. and Kadmon Corp. LLC market Syprine trientine hydrochloride...
BioCentury | Mar 24, 2014
Company News

EffRx, Kadmon deal

...indications. Kadmon has rights from Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX, Montreal, Quebec) to co-commercialize Syprine...
BioCentury | Mar 3, 2014
Company News

Kadmon, Valeant Pharmaceuticals sales and marketing update

...Pharmaceuticals North America LLC subsidiary granted Kadmon's Kadmon Pharmaceuticals LLC subsidiary U.S. co-commercialization rights to Syprine...
BioCentury | Nov 13, 2006
Clinical News

Coprexa: Pivotal trial data

...met the primary endpoint of a statistically significant reduction in incidence of neurologic worsening vs. Syprine...
...vs. 26%, p<0.05). Patients received Galzin zinc acetate maintenance therapy for a 2-year follow-up period. Syprine...
Items per page:
1 - 7 of 7